Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD22 | P20273 | 12/20 | 0.34 |
| ▸ | NANP | Q8TBE9 | 1/20 | 0.33 |
| ▸ | SELP | P16109 | 1/20 | 0.32 |
| ▸ | CAPN1 | P07384 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13948847 | 0.95 | CD22 (0.34) | CD22SELP | |
| SCHEMBL12341470 | 0.91 | CD22 (0.35) | CD22NANPCAPN1 | |
| SCHEMBL12341458 | 0.89 | NANP (0.38) | CD22NANPSELP | |
| SCHEMBL12341463 | 0.89 | CD22 (0.33) | CD22NANPSELPCAPN1 | |
| SCHEMBL10018768 | 0.88 | NANP (0.37) | CD22NANP | |
| SCHEMBL13948883 | 0.88 | NANP (0.37) | CD22NANP | |
| SCHEMBL13948849 | 0.88 | CD22 (0.34) | CD22CAPN1 | |
| SCHEMBL12341474 | 0.87 | CD22 (0.37) | CD22CAPN1 | |
| SCHEMBL13948842 | 0.87 | CD22 (0.37) | CD22NANPSELP | |
| SCHEMBL13948846 | 0.87 | CD22 (0.32) | CD22NANPSELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268967-B2 | Glycopegylated interferon α | NOVO NORDISK A/S (DK) | 2012-09-18 | — | — | US | disclosed |
| US-20090028822-A1 | Glycopegylated Interferon Alpha | NEOSE TECHNOLOGIES, INC. (US) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090028822-A1 | Glycopegylated Interferon Alpha | IFNG, IFNAR1, OGT | CD22 383/4885NANP 366/4885SELP 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.